Skip to main content
  • Not a healthcare professional? Visit our patient website
  • Visit our public site | Prescribing information | Adverse event reporting
  • Home
  • About Xenidate XL
  • About ADHD
  • Guidelines
  • Resources
  • Home
  • Why switch?
  • About Xenidate XL
  • About ADHD
  • Guidelines
  • Resources
  • References
  • References
  • Contact us
  • Privacy policy
  • T&Cs
  • Data Protection
  • Sitemap

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Viatris at pv.uk@viatris.com

Copyright © 2025 Viatris Inc. All rights reserved.

This website is owned and managed by Viatris. This website is intended for UK healthcare professionals only

Concerta XL is a registered trademark of Janssen-Cilag Ltd

Xenidate XL prolonged-release tablets are indicated as part of a comprehensive treatment programme for Attention Deficit/Hyperactivity Disorder (ADHD) in children aged 6 years of age and over and adults when remedial measures alone prove insufficient.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)